Last $3.40 USD
Change Today -0.0495 / -1.43%
Volume 2.2M
EXEL On Other Exchanges
As of 2:25 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $8.41
52 Week Low
04/15/14 - $3.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

227 Employees
Last Reported Date: 02/20/14
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $689.2K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $681.7K
Executive Vice President of Exelixis
Total Annual Compensation: $617.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $577.3K
Compensation as of Fiscal Year 2013.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Completes Planned Interim Analysis of the COMET-1 Phase 3 Pivotal Trial

On March 25, 2014, Exelixis, Inc. announced that the Independent Data Monitoring Committee (IDMC) notified the Company on March 25, 2014 that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. The company continues to anticipate top-line data from COMET-1 in 2014.

Exelixis, Inc. Receives Approval for COMETRIQ in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma

Exelixis, Inc. announced that the European Commission has approved COMETRIQ for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. The European Commission granted conditional marketing authorization following a positive opinion from the European Committee for Medicinal Products for Human Use issued in December 2013. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions. Additionally, the Committee for Orphan Medicinal Products during its January 2014 meeting reviewed the designation for COMETRIQ as an orphan medicinal product for the treatment of medullary thyroid carcinoma and recommended maintenance of orphan drug designation at the time of marketing authorization. The U.S. Food and Drug Administration approved COMETRIQ for the treatment of progressive, metastatic MTC in the United States on November 29, 2012. The approvals of COMETRIQ in both the United States and the European Union were based on data from EXAM, the international, multi-center, randomized double-blinded controlled phase 3 clinical trial conducted in 330 patients with progressive, unresectable locally advanced or metastatic MTC, in which cabozantinib met its primary efficacy endpoint of improving progression-free survival as compared to placebo. Please see Important Safety Information for COMETRIQ, including Boxed Warnings, below.

Exelixis, Inc. Announces Retirement of Frank McCormick as Director

Exelixis, Inc. announced that Frank McCormick, Ph.D., FRS, a member of the Board of Directors of the company, notified the company that he will retire from the Board at the end of his current term, which expires at the Company's 2014 Annual Meeting of Stockholders. Following receipt of Dr. McCormick's notice, on February 28, 2014 the Board reduced the size of the Board to 10 members, effective upon Dr. McCormick's retirement from the Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $3.41 USD -0.045

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.08 USD +0.28
Cell Therapeutics Inc $3.19 USD +0.0061
Cytokinetics Inc $13.20 USD +1.28
Evotec AG €3.65 EUR -0.004
Rigel Pharmaceuticals Inc $3.18 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.3x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at